Angeles Investment Advisors LLC Has $224,000 Stock Position in McKesson Co. (NYSE:MCK)

Angeles Investment Advisors LLC cut its holdings in shares of McKesson Co. (NYSE:MCK) by 4.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 393 shares of the company’s stock after selling 17 shares during the quarter. Angeles Investment Advisors LLC’s holdings in McKesson were worth $224,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Cerity Partners LLC increased its stake in McKesson by 7.6% during the third quarter. Cerity Partners LLC now owns 44,224 shares of the company’s stock valued at $21,867,000 after acquiring an additional 3,127 shares during the period. Penserra Capital Management LLC increased its position in shares of McKesson by 21.7% during the third quarter. Penserra Capital Management LLC now owns 1,075 shares of the company’s stock valued at $530,000 after purchasing an additional 192 shares during the period. Larson Financial Group LLC raised its stake in shares of McKesson by 4.3% in the third quarter. Larson Financial Group LLC now owns 1,141 shares of the company’s stock valued at $564,000 after purchasing an additional 47 shares in the last quarter. Centaurus Financial Inc. boosted its stake in McKesson by 518.4% during the third quarter. Centaurus Financial Inc. now owns 2,152 shares of the company’s stock worth $1,064,000 after buying an additional 1,804 shares in the last quarter. Finally, Summit Trail Advisors LLC increased its holdings in McKesson by 11.9% in the 3rd quarter. Summit Trail Advisors LLC now owns 1,401 shares of the company’s stock valued at $693,000 after buying an additional 149 shares during the period. 85.07% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Brian S. Tyler sold 8,961 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $597.99, for a total value of $5,358,588.39. Following the sale, the chief executive officer now directly owns 60,664 shares in the company, valued at $36,276,465.36. This trade represents a 12.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Leann B. Smith sold 579 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total transaction of $331,645.41. Following the completion of the sale, the executive vice president now owns 864 shares in the company, valued at approximately $494,890.56. This trade represents a 40.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,689 shares of company stock valued at $11,187,351. 0.11% of the stock is currently owned by insiders.

McKesson Trading Up 0.1 %

Shares of MCK stock opened at $661.56 on Tuesday. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $670.79. The firm’s 50 day moving average is $617.68 and its 200-day moving average is $575.39. The firm has a market capitalization of $82.91 billion, a price-to-earnings ratio of 30.29, a PEG ratio of 1.29 and a beta of 0.52.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. On average, equities research analysts forecast that McKesson Co. will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. The ex-dividend date is Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a yield of 0.43%. McKesson’s payout ratio is presently 13.00%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. StockNews.com lowered shares of McKesson from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Morgan Stanley lifted their price objective on McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Bank of America dropped their target price on McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a report on Monday, January 6th. Mizuho initiated coverage on McKesson in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $630.00 price target on the stock. Finally, Citigroup dropped their price objective on McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, McKesson presently has a consensus rating of “Moderate Buy” and an average price target of $649.36.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.